Drug giants give up on Alzheimer's cure
Research too difficult and costly, say pharmaceutical companies
Jeremy Laurance is a writer on health issues. He is former health editor of The Independent and the i and has covered the specialism for more than 20 years. He thinks the harm medicine does is under-appreciated, the harm it prevents over-rated, and that cycling works better than most drugs. He was named Specialist Journalist of the Year in the 2011 British Press Awards.
Wednesday 19 September 2012
The world's leading pharmaceutical companies are downgrading the search for new treatments for Alzheimer's disease after the failure of a series of high-profile drugs trials.
The human and financial costs of the disease are growing rapidly as the population ages, but the prospects of treatments to halt it, or slow its progress, are receding as at least five trials in the past five years have delivered disappointing results.
This year, a trial of Dimebon, backed by Pfizer, the US pharmaceutical giant, and reported in January, failed to show any benefit, instead costing the company $750m in lost investment.
In July, bapineuzumab, developed by Irish drug-maker Elan in association with Pfizer and the US multinational Johnson & Johnson, also failed to show an impact on symptoms.
In August, another US group, Eli Lilly, reported the failure of solanezumab, its second Alzheimer's drug to disappoint in two years. In 2010, a trial of semagacestat not only failed to slow the disease but worsened symptoms.
The setbacks have damaged confidence among drug makers in the field of neuroscience – brain research – which was already shaky.
Pharmaceutical manufacturers worldwide are under pressure and have been cutting back in the recession, but neuroscience has been disproportionately hit, with AstraZeneca, Pfizer, Merck, Sanofi, Novartis and GlaxoSmithKline all downsizing their European departments. Speaking at a briefing organised by the Science Media Centre yesterday, Eric Karran, director of research at Alzheimer's Research UK, said: "Neuroscience is a very challenging area. All companies are shedding jobs but neuroscience has had the highest attrition rate.
"AstraZeneca had a very large neuroscience group with some 300 scientists. It is reducing that to a team of 40, who will act as a virtual team – not doing their own research but monitoring developments and forging links with other companies."
Asked if the pipeline of new Alzheimer's drugs could run dry, he said: "That has always got to be a risk. My sense is not that companies want to move away [from Alzheimer's research] but that their shareholders are getting restive. That's capitalism – there is nothing we can do about that. But there is a huge public need."
At least 12 times as much was spent on cancer research as dementia research, yet dementia cost the country twice as much as cancer, he said.
Craig Ritchie, a leading Alzheimer's researcher at Imperial College, who runs a clinic for patients with dementia in west London, said: "The companies are streamlining their neuroscience departments and one can understand why. But it is hugely disappointing because there is massive unmet need.
"There is a shift to symptomatic treatments instead of disease-modifying ones. There is a lot less energy in the system than there used to be. We need a success story – a catalyst – to make people feel there is something to work towards."
Alzheimer's affects an estimated 500,000 people in the UK (a further 300,000 have other forms of dementia) and tens of millions worldwide, with the numbers expected to triple by 2050. It causes amnesia, loss of language, mood changes, apathy, psychosis and aggression.
The latest trials are thought to have failed because the drugs were given to patients too late in the disease process to have an effect, or were unable to pick up subtle changes in cognition over a relatively short period.
Alzheimer's, which is marked by the build-up of sticky protein clumps – amyloid plaques – in the brain, is thought to take at least 15 years to develop and by the time symptoms appear, it is too late to reverse.
Existing drugs, such as donepezil (Aricept), have limited benefits.
Geoffrey Macnab reviews American Hustle, also starring Christian Bale and Bradley Cooper
elephant appealThe first 23 lots in our charity auction have now gone. But there are 22 more still up for grabs
newsFormer soldier taped 33 of the animals to the floor and then stamped on them one by one
Michelle Nijhuis' daughter insists (s)he is, and she learnt a valuable lesson on gender in books
news Opponents claim it would stop performers such as Beyonce and Madonna appearing on TV
It takes a platoon of chefs, litres of brandy and rum, and almost 100kg of dried fruit
newsThat most ancient of crimes is on the rise, threatening farmers' livelihoods, community trust – and human health
food + drink
sportIf you thought the London Olympics and Wiggins' Tour glory made last year best, don't forget Murray's Wimbledon win and Farah's double
Life & Style blogs
The 10 Best Scotch Whiskies
America's 'virgin births'? One in 200 mothers 'became pregnant without having sex'
GTA 5: Rockstar bans gamers stealing in-game money worth millions
Microsoft announces first exclusive Xbox One content: a documentary on the worst video game ever
Potential revolution in cancer treatment voted breakthrough of the year by scientists
- 1 America's 'virgin births'? One in 200 mothers 'became pregnant without having sex'
- 2 North Koreans are gasping for the truth: Let's give it to them
- 3 Sun will 'flip upside down' within weeks, says Nasa
- 4 Christmas comes early: Justin Bieber is 'retiring from music'
- 5 Iain Duncan Smith leaves Commons food banks debate early
- < Previous
- Next >
£Negotiable: Citifocus: This is a new role carrying responsibility for a numbe...
£29999 - £40001 per annum + Benefits: Pro-Recruitment Group: A top independent...
£90 - £130 per day + contributory pension scheme: Randstad Education Mancheste...
£90 - £135 per day + contributory pension scheme: Randstad Education Mancheste...